Focused On-demand Library for HLA class II histocompatibility antigen, DM beta chain

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We use our state-of-the-art dedicated workflow for designing focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P28068

UPID:

DMB_HUMAN

Alternative names:

MHC class II antigen DMB; Really interesting new gene 7 protein

Alternative UPACC:

P28068; O77936; Q13012; Q29751; Q58ZE2; Q5SNZ8; Q5STC4; Q9XRX2

Background:

The HLA class II histocompatibility antigen, DM beta chain (HLA-DMB), plays a pivotal role in the immune system. It is essential for the catalytic release of class II-associated invariant chain peptide (CLIP) from MHC class II molecules, enabling the binding of antigenic peptides. This process is crucial in B-cells, where HLA-DM interacts with MHC class II molecules, a process regulated by HLA-DO. Known alternatively as MHC class II antigen DMB and Really interesting new gene 7 protein, HLA-DMB is integral to immune response modulation.

Therapeutic significance:

Understanding the role of HLA class II histocompatibility antigen, DM beta chain, could open doors to potential therapeutic strategies.